<p>Immunocore Holdings plc has released a new corporate presentation detailing its advancements in immunomodulating medicines. The document highlights the company’s bispecific, soluble T cell receptor (TCR) platform, which targets more than 90% of the human proteome. Immunocore’s pipeline covers three main therapeutic areas: oncology, infectious diseases, and autoimmune diseases, with lead programs including ImmTAC, ImmTAV, and ImmTAAI therapies, each designed to either activate or downmodulate the immune system. The presentation emphasizes the performance of KIMMTRAK® in HLA-A02-positive metastatic uveal melanoma, noting a median overall survival of 28 months and 27% three-year survival in treated patients, compared to 18% for investigator’s choice. The company also reports high market penetration rates and sustained commercial growth for KIMMTRAK®. Pipeline developments include candidates targeting advanced cutaneous melanoma, colorectal and GI cancers, HIV, type 1 diabetes, and atopic dermatitis. Five-year overall survival data for KIMMTRAK® are expected in the first half of 2026. You can access the full presentation through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunocore Holdings plc published the original content used to generate this news brief on January 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</p>

Immunocore Unveils Pipeline Advances in TCR Therapies for Cancer, Infectious, and Autoimmune Diseases